Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

TIM-3 antagonist

DRUG CLASS:

TIM-3 antagonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	MBG453 Sensitive: B - Late Trials MBG453 Sensitive : B	MBG453 Sensitive: B - Late Trials MBG453 Sensitive : B
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	MBG453 Sensitive: C3 – Early Trials MBG453 Sensitive : C3	MBG453 Sensitive: C3 – Early Trials MBG453 Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	MBG453 Sensitive: C3 – Early Trials MBG453 Sensitive : C3	MBG453 Sensitive: C3 – Early Trials MBG453 Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	azacitidine + MBG453 Sensitive: C3 – Early Trials azacitidine + MBG453 Sensitive : C3	azacitidine + MBG453 Sensitive: C3 – Early Trials azacitidine + MBG453 Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	decitabine + MBG453 Sensitive: C3 – Early Trials decitabine + MBG453 Sensitive : C3	decitabine + MBG453 Sensitive: C3 – Early Trials decitabine + MBG453 Sensitive : C3
IL6 underexpression	Non Small Cell Lung Cancer	IL6 underexpression	Non Small Cell Lung Cancer	dostarlimab-gxly + TSR-022 Sensitive: C3 – Early Trials dostarlimab-gxly + TSR-022 Sensitive : C3	dostarlimab-gxly + TSR-022 Sensitive: C3 – Early Trials dostarlimab-gxly + TSR-022 Sensitive : C3
CXCL8 underexpression	Non Small Cell Lung Cancer	CXCL8 underexpression	Non Small Cell Lung Cancer	dostarlimab-gxly + TSR-022 Sensitive: C3 – Early Trials dostarlimab-gxly + TSR-022 Sensitive : C3	dostarlimab-gxly + TSR-022 Sensitive: C3 – Early Trials dostarlimab-gxly + TSR-022 Sensitive : C3
HAVCR2 overexpression	Non Small Cell Lung Cancer	HAVCR2 overexpression	Non Small Cell Lung Cancer	dostarlimab-gxly + TSR-022 Sensitive: C3 – Early Trials dostarlimab-gxly + TSR-022 Sensitive : C3	dostarlimab-gxly + TSR-022 Sensitive: C3 – Early Trials dostarlimab-gxly + TSR-022 Sensitive : C3
MECOM rearrangement	Myelodysplastic Syndrome	MECOM rearrangement	Myelodysplastic Syndrome	MBG453 Sensitive: C4 – Case Studies MBG453 Sensitive : C4	MBG453 Sensitive: C4 – Case Studies MBG453 Sensitive : C4